Aimmune Therapeutics, Inc. Appoints Daniel Adelman, M.D., as Chief Medical Officer
June 21, 2016 at 07:00 am EDT
Aimmune Therapeutics, Inc. announced the appointment of Daniel C. Adelman, M.D., as Chief Medical Officer. Dr. Adelman, officially assumed his new role on June 16, 2016. Until resigning to become Chief Medical Officer of Aimmune, Dr. Adelman was a member of the prestigious Research Advisory Board of Food Allergy Research & Education (FARE). Most recently, Dr. Adelman spent seven years as Chief Medical Officer and Senior Vice President of Development at Alvine Pharmaceuticals.